Vilaterm Inhaler is an advanced and highly effective combination medication that provides powerful, dual-action therapy for the long-term management of chronic respiratory diseases. It contains a precise dose of Vilanterol (25 mcg), a long-acting beta-2 agonist (LABA), and Fluticasone Furoate (200 mcg), a potent inhaled corticosteroid (ICS). This strategic ICS-LABA combination works synergistically to address both the underlying inflammation in the airways and the immediate bronchospasm, offering a level of control and symptom prevention that is superior to monotherapy. It is an essential component of daily maintenance therapy for patients with moderate to severe asthma and COPD.
The respiratory segment of the Indian pharmaceutical market is a high-volume, high-value sector with a consistently high demand. The rising prevalence of respiratory disorders, fueled by factors such as increasing air pollution, smoking, and an aging population, ensures a continuous and robust need for advanced maintenance therapies. Products like Vilaterm Inhaler represent a premium category in the pulmonology segment, with a stable prescription base from specialists. This makes it a strategic choice for any distributor seeking a stable and profitable business, as its essential nature guarantees a steady and predictable revenue stream.
We are dedicated to empowering our franchise partners with all the tools necessary for success. Our product, manufactured in a WHO-GMP certified facility, ensures impeccable quality, efficacy, and safety, which is crucial for building trust with healthcare professionals and patients. We provide a complete promotional and marketing kit, including visual aids and product literature, to support your sales efforts. Our robust supply chain guarantees timely delivery and continuous stock availability, preventing any business interruptions. Partner with us to enter this stable and highly profitable market and establish a reputable and successful business as a key supplier of this top-quality respiratory medicine.